数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Dwight H. Egan Chief Executive Officer, President and Chairman of the Board 69 196.71万美元 5.00 2023-07-20
Richard S. Serbin Director 78 51.66万美元 4.55 2023-07-20
Eugene Durenard Director 53 51.66万美元 未持股 2023-07-20
Edward L. Murphy Director 58 51.66万美元 未持股 2023-07-20
James Nelson Director 70 51.66万美元 未持股 2023-07-20

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Dwight H. Egan Chief Executive Officer, President and Chairman of the Board 69 196.71万美元 5.00 2023-07-20
Brian Brown Chief Financial Officer and Secretary 47 157.78万美元 未持股 2023-07-20

董事简历

中英对照 |  中文 |  英文
Dwight H. Egan

DwightH.Egan自2013年4月以来一直担任高级职员和董事。Egan先生从1999年2月到现在一直从事私人投资业务。他曾担任Data Broadcasting Corporation(无线、实时金融市场数据、新闻和复杂的固定收益投资组合分析的领先供应商,面向27000名个人和专业投资者)的高级执行官(1995年至1999年)。他从1984年到1995年共同创立并担任Broadcasting International,Inc.的首席执行官和董事会主席,当时Data Broadcasting Corporation收购Broadcasting International并创建领先的金融新闻网站CBS MarketWatch并参与其首次公开募股。


Dwight H. Egan,serves as Co-Diagnostics, Inc. President and Chief Executive Officer and has been an officer and director of the Company since April 2013. Mr. Egan has been engaged in private investment business from February 1999 to the present. He was a senior executive at Data Broadcasting Corporation, a leading provider of wireless, real-time financial market data, news and sophisticated fixed- income portfolio analytics to 27,000 individual and professional investors from 1995 to 1999. He co-founded and served as CEO and Chairman of the Board of Broadcast International, Inc. from 1984 to 1995, when Data Broadcasting Corporation acquired Broadcast International and created CBS MarketWatch, a leading financial news site and participated in its initial public offering.
DwightH.Egan自2013年4月以来一直担任高级职员和董事。Egan先生从1999年2月到现在一直从事私人投资业务。他曾担任Data Broadcasting Corporation(无线、实时金融市场数据、新闻和复杂的固定收益投资组合分析的领先供应商,面向27000名个人和专业投资者)的高级执行官(1995年至1999年)。他从1984年到1995年共同创立并担任Broadcasting International,Inc.的首席执行官和董事会主席,当时Data Broadcasting Corporation收购Broadcasting International并创建领先的金融新闻网站CBS MarketWatch并参与其首次公开募股。
Dwight H. Egan,serves as Co-Diagnostics, Inc. President and Chief Executive Officer and has been an officer and director of the Company since April 2013. Mr. Egan has been engaged in private investment business from February 1999 to the present. He was a senior executive at Data Broadcasting Corporation, a leading provider of wireless, real-time financial market data, news and sophisticated fixed- income portfolio analytics to 27,000 individual and professional investors from 1995 to 1999. He co-founded and served as CEO and Chairman of the Board of Broadcast International, Inc. from 1984 to 1995, when Data Broadcasting Corporation acquired Broadcast International and created CBS MarketWatch, a leading financial news site and participated in its initial public offering.
Richard S. Serbin

RichardS.Serbin于2017年5月加入我们的董事会,目前担任梦百合行业许多公司的顾问。他曾担任Life Science Institute,LLC的公司发展总裁兼内部法律顾问(2013年6月1日至2014年7月15日)。Serbin先生是一名全球战略顾问、药剂师和企业家,拥有药剂学和法律方面的证书,并在梦百合行业担任了40多年的FDA监管律师和专利律师。他于2017年1月被任命为Cure Pharmaceutical的咨询委员会成员,并自2015年9月起担任Prime Access,Inc.的咨询委员会成员。Serbin先生自2014年11月18日起担任Rapid Nutrition plc的董事。他从2013年5月到2014年6月担任ViroPro Inc.董事。他从2006年10月到2007年9月担任Mazal Plant Pharmaceuticals Inc.业务顾问委员会主管,也曾担任其业务顾问委员会成员。他从2002年7月到2005年9月15日担任Optigenex Inc.的首席执行官,从2004年7月到2005年9月担任董事。Serbin从1999年1月到2002年7月担任多家制药公司顾问。他曾担任Bradley Pharmaceuticals的总裁。他曾担任Ortho Pharmaceuticals公司(强生公司的子公司)的企业发展Vice President,并在露华浓强生公司公司和先灵葆雅公司实践专利和FDA法律。他曾担任Schering Plough Corporation的专利律师,以及Revlon Corporation、Johnson and Johnson Corporation的首席FDA法律顾问。随后,他在露华浓公司(Revlon Corporation)工作,担任其首席食品、药品和化妆品顾问。他创立了Radius Scientific Corporation。他曾担任强生公司(J&;J&;8217;)的企业发展Vice President,后来领导了一家基于斯坦福医学院(Stanford Medical School)开发的技术的成功上市公司。Serbin先生职业生涯的很大一部分时间专注于国际市场和客户。在J&J时,Serbin先生担任16家美国和国际子公司的董事会成员,包括Ethicon,Ortho,J&J Consumer Products,Pittman-Moore,MC Neil和J&J Development Corporation。他曾从事多个国际收购和战略关系,并任职其几个国际子公司的董事会,包括印度、香港、日本、台湾、德国和英国的子公司。Serbin先生拥有罗格斯大学(Rutgers University)和罗格斯大学药学院(Rutgers University College of Pharmacy)的B.S.和B.Pharmacy,Seton Hall法学院的法学博士学位和纽约大学法学院(NYU Law School)的贸易法规和法律硕士学位。


has been a member of Co-Diagnostics, Inc. board of directors since May 2017. Mr. Serbin currently serves as a consultant to many companies in the healthcare industry. He was the President of Corporate Development and In-House Legal Counsel at Life Science Institute, LLC, from June 1, 2013 to July 15, 2014. He was appointed to the Advisory Board of Cure Pharmaceutical in January 2017. He served as Director at Viropro Inc. from May 2013 to June 2014. He was Head of Business Advisory Board at Mazal Plant Pharmaceuticals Inc. from October 2006 to September 2007 and also served as its Member of Business Advisory Board. He served as Chief Executive Officer of Optigenex Inc. from July 2002 to September 15, 2005 and a director from July 2004 to September 2005. From January 1999 until July 2002 Mr. Serbin served as a consultant to various pharmaceutical companies. He served as the President of Bradley Pharmaceuticals. He served as Vice President of Corporate Development at Ortho Pharmaceuticals, a Johnson & Johnson subsidiary, as well as serving on multiple domestic and international Boards of Directors of Johnson & Johnson subsidiary divisions. He practiced Patent and FDA law at Revlon Johnson & Johnson and Schering-Plough. He served as Patent Attorney for Schering Plough Corporation and Chief FDA Counsel for Revlon Corporation and Johnson and Johnson Corporation. Subsequently, he worked at Revlon Corporation, as its Chief Food, Drug and Cosmetic Counsel. He founded Radius Scientific Corporation. He was J&J's Vice President of Corporate Development, and later led a successful public offering venture based on technology developed at Stanford Medical School. Mr. Serbin spent a large portion of his career focusing on international markets and clients. While at J&J, Mr. Serbin served on the board of directors of 16 US and international subsidiary companies, including Ethicon, Ortho, J&J Consumer Products, Pittman-Moore, Mc Neil, and J&J Development Corporation. He worked on multiple international acquisitions and strategic relationships, and sat on the board of directors of several of its international subsidiaries, including those in India, Hong Kong, Japan, Taiwan, Germany, and England. Mr. Serbin has a B.S. and a B. Pharmacy from Rutgers University and Rutgers University College of Pharmacy, a J.D. degree from Seton Hall Law School and a Master's Degree in Trade Regulations and Law from NYU Law School.
RichardS.Serbin于2017年5月加入我们的董事会,目前担任梦百合行业许多公司的顾问。他曾担任Life Science Institute,LLC的公司发展总裁兼内部法律顾问(2013年6月1日至2014年7月15日)。Serbin先生是一名全球战略顾问、药剂师和企业家,拥有药剂学和法律方面的证书,并在梦百合行业担任了40多年的FDA监管律师和专利律师。他于2017年1月被任命为Cure Pharmaceutical的咨询委员会成员,并自2015年9月起担任Prime Access,Inc.的咨询委员会成员。Serbin先生自2014年11月18日起担任Rapid Nutrition plc的董事。他从2013年5月到2014年6月担任ViroPro Inc.董事。他从2006年10月到2007年9月担任Mazal Plant Pharmaceuticals Inc.业务顾问委员会主管,也曾担任其业务顾问委员会成员。他从2002年7月到2005年9月15日担任Optigenex Inc.的首席执行官,从2004年7月到2005年9月担任董事。Serbin从1999年1月到2002年7月担任多家制药公司顾问。他曾担任Bradley Pharmaceuticals的总裁。他曾担任Ortho Pharmaceuticals公司(强生公司的子公司)的企业发展Vice President,并在露华浓强生公司公司和先灵葆雅公司实践专利和FDA法律。他曾担任Schering Plough Corporation的专利律师,以及Revlon Corporation、Johnson and Johnson Corporation的首席FDA法律顾问。随后,他在露华浓公司(Revlon Corporation)工作,担任其首席食品、药品和化妆品顾问。他创立了Radius Scientific Corporation。他曾担任强生公司(J&;J&;8217;)的企业发展Vice President,后来领导了一家基于斯坦福医学院(Stanford Medical School)开发的技术的成功上市公司。Serbin先生职业生涯的很大一部分时间专注于国际市场和客户。在J&J时,Serbin先生担任16家美国和国际子公司的董事会成员,包括Ethicon,Ortho,J&J Consumer Products,Pittman-Moore,MC Neil和J&J Development Corporation。他曾从事多个国际收购和战略关系,并任职其几个国际子公司的董事会,包括印度、香港、日本、台湾、德国和英国的子公司。Serbin先生拥有罗格斯大学(Rutgers University)和罗格斯大学药学院(Rutgers University College of Pharmacy)的B.S.和B.Pharmacy,Seton Hall法学院的法学博士学位和纽约大学法学院(NYU Law School)的贸易法规和法律硕士学位。
has been a member of Co-Diagnostics, Inc. board of directors since May 2017. Mr. Serbin currently serves as a consultant to many companies in the healthcare industry. He was the President of Corporate Development and In-House Legal Counsel at Life Science Institute, LLC, from June 1, 2013 to July 15, 2014. He was appointed to the Advisory Board of Cure Pharmaceutical in January 2017. He served as Director at Viropro Inc. from May 2013 to June 2014. He was Head of Business Advisory Board at Mazal Plant Pharmaceuticals Inc. from October 2006 to September 2007 and also served as its Member of Business Advisory Board. He served as Chief Executive Officer of Optigenex Inc. from July 2002 to September 15, 2005 and a director from July 2004 to September 2005. From January 1999 until July 2002 Mr. Serbin served as a consultant to various pharmaceutical companies. He served as the President of Bradley Pharmaceuticals. He served as Vice President of Corporate Development at Ortho Pharmaceuticals, a Johnson & Johnson subsidiary, as well as serving on multiple domestic and international Boards of Directors of Johnson & Johnson subsidiary divisions. He practiced Patent and FDA law at Revlon Johnson & Johnson and Schering-Plough. He served as Patent Attorney for Schering Plough Corporation and Chief FDA Counsel for Revlon Corporation and Johnson and Johnson Corporation. Subsequently, he worked at Revlon Corporation, as its Chief Food, Drug and Cosmetic Counsel. He founded Radius Scientific Corporation. He was J&J's Vice President of Corporate Development, and later led a successful public offering venture based on technology developed at Stanford Medical School. Mr. Serbin spent a large portion of his career focusing on international markets and clients. While at J&J, Mr. Serbin served on the board of directors of 16 US and international subsidiary companies, including Ethicon, Ortho, J&J Consumer Products, Pittman-Moore, Mc Neil, and J&J Development Corporation. He worked on multiple international acquisitions and strategic relationships, and sat on the board of directors of several of its international subsidiaries, including those in India, Hong Kong, Japan, Taiwan, Germany, and England. Mr. Serbin has a B.S. and a B. Pharmacy from Rutgers University and Rutgers University College of Pharmacy, a J.D. degree from Seton Hall Law School and a Master's Degree in Trade Regulations and Law from NYU Law School.
Eugene Durenard

Eugene Durenard于2019年6月加入我们的董事会,他是Dyperbolic Holdings的创始人兼首席执行官,该公司是一家总部位于瑞士的控股,管理咨询和战略咨询公司,专门从事梦百合。Eugene拥有跨越20年的投资和创业经验。在过去的7年里,他一直与家族办公室合作,从事直接投资和专注于生命科学的慈善事业。他是生物技术和医疗技术领域几家私营公司的顾问委员会成员,也是专注于梦百合的Impact Venture Fund的成员。在伦敦所罗门兄弟(Salomon Brothers)和瑞士信贷(Credit Suisse)从事自营研究和交易的最初职业生涯后,他在百慕大联合创立了猎户座投资管理公司(Orion Investment Management),专门从事机构和私人客户的量化资产负债管理。他随后将其出售给Capital G Bank,并共同领导他们的资产管理。尤金花了几年时间与全球40多个生命科学创新集群的代表、经营梦百合企业的家庭和行业领袖建立了个人联系。他定期访问实验室和孵化器,会见领先的科学家和创新者,以跟上当前的趋势和发展。他的建议是基于结合科学的深入知识、竞争力和金融专业知识的透彻分析。他在资产负债管理行业杂志上发表了多篇文章,并在2013年出版了《专业自动化交易理论与实践》一书。他获有Harvard University数学博士学位。


has been a member of Co-Diagnostics, Inc. board of directors since June 2019. Dr. Durenard is the Founder and CEO of Hyperbolic Holdings, a Swiss-based holding, management consulting and strategy advisory company specialized in healthcare. For the last 7 years he has been working with family offices on direct investments and philanthropy focused on life sciences. He serves on the advisory board of several private companies in the biotech and MedTech sectors. After an initial career in proprietary research and trading at Salomon Brothers and Credit Suisse in London, he co-founded Orion Investment Management in Bermuda specializing in quantitative asset and liability management for institutions and private clients. He subsequently sold it to Capital G Bank and co-headed their asset management. Dr. Durenard spent several years establishing personal connections with representatives of 40+ clusters of life science innovation, families operating healthcare businesses and industry leaders globally. He regularly visits labs and incubators, meets with leading scientists and innovators in order to keep abreast of current trends and developments. His advice is based on a thorough analysis that combines in-depth knowledge of science, competitive forces and financial expertise. He has published several articles in asset-liability management industry magazines as well as the book "Professional Automated Trading — Theory and Practice" (Wiley 2013). He has a PhD in Mathematics from Harvard University.
Eugene Durenard于2019年6月加入我们的董事会,他是Dyperbolic Holdings的创始人兼首席执行官,该公司是一家总部位于瑞士的控股,管理咨询和战略咨询公司,专门从事梦百合。Eugene拥有跨越20年的投资和创业经验。在过去的7年里,他一直与家族办公室合作,从事直接投资和专注于生命科学的慈善事业。他是生物技术和医疗技术领域几家私营公司的顾问委员会成员,也是专注于梦百合的Impact Venture Fund的成员。在伦敦所罗门兄弟(Salomon Brothers)和瑞士信贷(Credit Suisse)从事自营研究和交易的最初职业生涯后,他在百慕大联合创立了猎户座投资管理公司(Orion Investment Management),专门从事机构和私人客户的量化资产负债管理。他随后将其出售给Capital G Bank,并共同领导他们的资产管理。尤金花了几年时间与全球40多个生命科学创新集群的代表、经营梦百合企业的家庭和行业领袖建立了个人联系。他定期访问实验室和孵化器,会见领先的科学家和创新者,以跟上当前的趋势和发展。他的建议是基于结合科学的深入知识、竞争力和金融专业知识的透彻分析。他在资产负债管理行业杂志上发表了多篇文章,并在2013年出版了《专业自动化交易理论与实践》一书。他获有Harvard University数学博士学位。
has been a member of Co-Diagnostics, Inc. board of directors since June 2019. Dr. Durenard is the Founder and CEO of Hyperbolic Holdings, a Swiss-based holding, management consulting and strategy advisory company specialized in healthcare. For the last 7 years he has been working with family offices on direct investments and philanthropy focused on life sciences. He serves on the advisory board of several private companies in the biotech and MedTech sectors. After an initial career in proprietary research and trading at Salomon Brothers and Credit Suisse in London, he co-founded Orion Investment Management in Bermuda specializing in quantitative asset and liability management for institutions and private clients. He subsequently sold it to Capital G Bank and co-headed their asset management. Dr. Durenard spent several years establishing personal connections with representatives of 40+ clusters of life science innovation, families operating healthcare businesses and industry leaders globally. He regularly visits labs and incubators, meets with leading scientists and innovators in order to keep abreast of current trends and developments. His advice is based on a thorough analysis that combines in-depth knowledge of science, competitive forces and financial expertise. He has published several articles in asset-liability management industry magazines as well as the book "Professional Automated Trading — Theory and Practice" (Wiley 2013). He has a PhD in Mathematics from Harvard University.
Edward L. Murphy

EdwardL.Murphy于2019年6月加入我们的董事会,目前担任私人投资公司Dover Investments Ltd.的高级副总裁和合伙人。在他的整个职业生涯中,Murphy&8217;先生的职责包括房地产和金融服务的各种类型的投资项目的投资分析。目前,Murphy先生任职于几家加拿大公开报告公司的董事会,这些公司在各个行业都有利益。他自2016年1月以来一直担任Empire Minerals Corporation Inc.的董事,自2011年6月以来一直担任DigiCrypts Blockchain Solutions Inc.的董事,自2018年2月以来一直担任Lakefield Marketing Corporation的董事,自1997年4月30日以来一直担任Mosport Park Entertainment Corporation的董事。他于2003年5月至2017年12月担任Aurquest Resources的董事。


Edward L. Murphy,has been a member of Co-Diagnostics, Inc. board of directors since June 2019. Since December 1999, Mr. Murphy has served as a senior vice president and a partner of Dover Investments Ltd., a private investment firm. Throughout his career, Mr. Murphy''s duties have included investment analysis of various types of investment projects in real estate and financial services. Currently, Mr. Murphy serves on the board of directors of several Canadian publicly reporting companies that have interests in various industries. He has been a Director at Empire Minerals Corporation Inc. since January 2016, at Digicrypts Blockchain Solutions Inc. from June 2011 to November 2022, at Lakefield Marketing Corporation since February 2018, CEO/CFO and Director of Credo Resources Inc. since September 2019, at the Mosport Park Entertainment Corporation since April 30, 1997, at Essex Oil Ltd. Since July 2021, and at Darkhorse Technologies Ltd. since November 2021. He served as a Director at Aurquest Resources from May 2003 to December 2017.
EdwardL.Murphy于2019年6月加入我们的董事会,目前担任私人投资公司Dover Investments Ltd.的高级副总裁和合伙人。在他的整个职业生涯中,Murphy&8217;先生的职责包括房地产和金融服务的各种类型的投资项目的投资分析。目前,Murphy先生任职于几家加拿大公开报告公司的董事会,这些公司在各个行业都有利益。他自2016年1月以来一直担任Empire Minerals Corporation Inc.的董事,自2011年6月以来一直担任DigiCrypts Blockchain Solutions Inc.的董事,自2018年2月以来一直担任Lakefield Marketing Corporation的董事,自1997年4月30日以来一直担任Mosport Park Entertainment Corporation的董事。他于2003年5月至2017年12月担任Aurquest Resources的董事。
Edward L. Murphy,has been a member of Co-Diagnostics, Inc. board of directors since June 2019. Since December 1999, Mr. Murphy has served as a senior vice president and a partner of Dover Investments Ltd., a private investment firm. Throughout his career, Mr. Murphy''s duties have included investment analysis of various types of investment projects in real estate and financial services. Currently, Mr. Murphy serves on the board of directors of several Canadian publicly reporting companies that have interests in various industries. He has been a Director at Empire Minerals Corporation Inc. since January 2016, at Digicrypts Blockchain Solutions Inc. from June 2011 to November 2022, at Lakefield Marketing Corporation since February 2018, CEO/CFO and Director of Credo Resources Inc. since September 2019, at the Mosport Park Entertainment Corporation since April 30, 1997, at Essex Oil Ltd. Since July 2021, and at Darkhorse Technologies Ltd. since November 2021. He served as a Director at Aurquest Resources from May 2003 to December 2017.
James Nelson

James Nelson是Sunworks,Inc.的退休董事长兼首席执行官,这是一家纳斯达克上市的商业、农业和住宅太阳能集成商,他在2010年10月帮助创立了该公司。Nelson先生目前担任另外三家上市公司的战略顾问。Jim职业生涯的大部分时间都在Private Equity任职,担任Peterson Partners和Millennial Capital Partners的普通合伙人。除了他的投资和财务责任,他曾担任他的两个公司(投资组合公司)的首席执行官。在从事私募股权投资之前,纳尔逊先生曾担任Banana Republic的市场营销Vice President,在那里他管理公司范围内的市场营销,以及公司的国际扩张计划。他也曾担任Banana Republic公司的目录部门总经理。他曾担任SAGA Corporation(一家数十亿美元的食品服务公司)的营销和企业发展Vice President。Jim于35年前在Bain and Company(一家商业战略咨询公司)开始他的执行职业生涯,在那里他管理四大洲的顾问团队。Nelson先生在杨百翰大学(Brigham Young University)获得工商管理硕士学位,在那里他以优等成绩毕业,并被评为杰出的工商管理硕士毕业生。


has been a member of Co-Diagnostics, Inc. board of directors since June 2019. Mr. Nelson is the retired Chairman and CEO of Sunworks, Inc., a NASDAQ traded commercial, agriculture, and residential solar Integrator which he helped found in October 2010. Mr. Nelson spent most of his career working in private equity as a general partner with Peterson Partners and with Millennial Capital Partners. In addition to his investment and financial responsibilities, he served as CEO of two of his firms' portfolio companies. Prior to his years in private equity, Mr. Nelson served as Vice President of Marketing at Banana Republic, where he managed company-wide marketing, as well as the company's international expansion initiative. He was also general manager for Banana Republic's catalog division. He was Vice President of Marketing and Corporate Development at Saga Corporation, a multi-billion-dollar food service company. Mr. Nelson began his executive career over 35 years ago at Bain and Company, a business strategy consulting firm, where he managed teams of consultants on four continents. Mr. Nelson received his MBA from Brigham Young University, where he graduated summa cum laude and was named the Outstanding Master of Business Administration Graduate.
James Nelson是Sunworks,Inc.的退休董事长兼首席执行官,这是一家纳斯达克上市的商业、农业和住宅太阳能集成商,他在2010年10月帮助创立了该公司。Nelson先生目前担任另外三家上市公司的战略顾问。Jim职业生涯的大部分时间都在Private Equity任职,担任Peterson Partners和Millennial Capital Partners的普通合伙人。除了他的投资和财务责任,他曾担任他的两个公司(投资组合公司)的首席执行官。在从事私募股权投资之前,纳尔逊先生曾担任Banana Republic的市场营销Vice President,在那里他管理公司范围内的市场营销,以及公司的国际扩张计划。他也曾担任Banana Republic公司的目录部门总经理。他曾担任SAGA Corporation(一家数十亿美元的食品服务公司)的营销和企业发展Vice President。Jim于35年前在Bain and Company(一家商业战略咨询公司)开始他的执行职业生涯,在那里他管理四大洲的顾问团队。Nelson先生在杨百翰大学(Brigham Young University)获得工商管理硕士学位,在那里他以优等成绩毕业,并被评为杰出的工商管理硕士毕业生。
has been a member of Co-Diagnostics, Inc. board of directors since June 2019. Mr. Nelson is the retired Chairman and CEO of Sunworks, Inc., a NASDAQ traded commercial, agriculture, and residential solar Integrator which he helped found in October 2010. Mr. Nelson spent most of his career working in private equity as a general partner with Peterson Partners and with Millennial Capital Partners. In addition to his investment and financial responsibilities, he served as CEO of two of his firms' portfolio companies. Prior to his years in private equity, Mr. Nelson served as Vice President of Marketing at Banana Republic, where he managed company-wide marketing, as well as the company's international expansion initiative. He was also general manager for Banana Republic's catalog division. He was Vice President of Marketing and Corporate Development at Saga Corporation, a multi-billion-dollar food service company. Mr. Nelson began his executive career over 35 years ago at Bain and Company, a business strategy consulting firm, where he managed teams of consultants on four continents. Mr. Nelson received his MBA from Brigham Young University, where he graduated summa cum laude and was named the Outstanding Master of Business Administration Graduate.

高管简历

中英对照 |  中文 |  英文
Dwight H. Egan

DwightH.Egan自2013年4月以来一直担任高级职员和董事。Egan先生从1999年2月到现在一直从事私人投资业务。他曾担任Data Broadcasting Corporation(无线、实时金融市场数据、新闻和复杂的固定收益投资组合分析的领先供应商,面向27000名个人和专业投资者)的高级执行官(1995年至1999年)。他从1984年到1995年共同创立并担任Broadcasting International,Inc.的首席执行官和董事会主席,当时Data Broadcasting Corporation收购Broadcasting International并创建领先的金融新闻网站CBS MarketWatch并参与其首次公开募股。


Dwight H. Egan,serves as Co-Diagnostics, Inc. President and Chief Executive Officer and has been an officer and director of the Company since April 2013. Mr. Egan has been engaged in private investment business from February 1999 to the present. He was a senior executive at Data Broadcasting Corporation, a leading provider of wireless, real-time financial market data, news and sophisticated fixed- income portfolio analytics to 27,000 individual and professional investors from 1995 to 1999. He co-founded and served as CEO and Chairman of the Board of Broadcast International, Inc. from 1984 to 1995, when Data Broadcasting Corporation acquired Broadcast International and created CBS MarketWatch, a leading financial news site and participated in its initial public offering.
DwightH.Egan自2013年4月以来一直担任高级职员和董事。Egan先生从1999年2月到现在一直从事私人投资业务。他曾担任Data Broadcasting Corporation(无线、实时金融市场数据、新闻和复杂的固定收益投资组合分析的领先供应商,面向27000名个人和专业投资者)的高级执行官(1995年至1999年)。他从1984年到1995年共同创立并担任Broadcasting International,Inc.的首席执行官和董事会主席,当时Data Broadcasting Corporation收购Broadcasting International并创建领先的金融新闻网站CBS MarketWatch并参与其首次公开募股。
Dwight H. Egan,serves as Co-Diagnostics, Inc. President and Chief Executive Officer and has been an officer and director of the Company since April 2013. Mr. Egan has been engaged in private investment business from February 1999 to the present. He was a senior executive at Data Broadcasting Corporation, a leading provider of wireless, real-time financial market data, news and sophisticated fixed- income portfolio analytics to 27,000 individual and professional investors from 1995 to 1999. He co-founded and served as CEO and Chairman of the Board of Broadcast International, Inc. from 1984 to 1995, when Data Broadcasting Corporation acquired Broadcast International and created CBS MarketWatch, a leading financial news site and participated in its initial public offering.
Brian Brown

Brian Brown成为Co-diagnostics,Inc.首席财务官于2021年2月。从2020年7月到2021年2月,Brown先生担任A-Core Concrete Cutting,Inc.的首席财务官,在那里他的职责包括监督公司的会计和财务部门,并购,并负责财务预测和预算。从2019年8月到2019年12月,Brown先生担任Sportsman’;S Warehouse Holdings,Inc.的会计、财务和投资者关系副总裁,这是一家上市公司,在纳斯达克全球精选上市,代码为SPWH,他的职责包括监管公司的会计、财务和投资者关系部门,与美国证券交易委员会一起准备公司的年度、季度和当前报告,监督公司年度审计的所有方面,包括但不限于审计支持时间表的准备和审查,财务报表和脚注的准备,并为公司的独立审计师提供支持。从2009年10月到2019年8月,他担任Sportsman’;S Warehouse Holdings,Inc.的财务总监,在那里他协助公司于2014年4月进行首次公开募股,以及进行私人和第二次公开募股,根据《交易法》和《萨班斯·奥克斯利法案》,收购一批零售商店,并为公司准备提交给证券交易委员会的定期报告和最新报告。从2005年5月到2009年10月,他担任Franklin Covey Products的公司财务总监,在那里他根据Sarbanes Oxley Act第404条所要求的控制标准开发和维护公司的财务报告结构内部控制。从2001年7月到2005年5月,他担任毕马威会计师事务所(KPMG,LLP)的高级鉴证人员,在那里他为多个行业的各种客户提供审计服务。Brown先生拥有犹他大学的会计学文学学士学位和专业会计硕士学位。布朗先生是犹他州的注册会计师。


Brian Brown,became Co-Diagnostics, Inc. Chief Financial Officer in February 2021. From July 2020 until February 2021, Mr. Brown served as the Chief Financial Officer of A-Core Concrete Cutting, Inc. where his duties included overseeing the company''s accounting and finance departments, mergers and acquisitions and responsibility for financial forecasting and budgeting. From January 2020 to July 2020, Mr. Brown was an independent consultant. From August 2019 to December 2019, Mr. Brown served as the Vice President of Accounting, Treasury and Investor Relations at Sportsman''s Warehouse Holdings, Inc., a public company reporting on Nasdaq Global Select under the symbol SPWH, where his duties included overseeing the company''s accounting, treasury and investor relations departments, preparing the company''s annual, quarterly and current reports with the SEC, overseeing all aspects of the company''s annual audit, including, but not limited to, the preparation and review of audit support schedules, preparation of financial statements and footnotes, and providing support to the company''s independent auditors. From October 2009 to August 2019, Mr. Brown served as the Director of Finance of Sportsman''s Warehouse Holdings, Inc. where he assisted with the company''s initial public offering in April 2014 as well as effecting private and secondary public offerings, acquisitions of a group of retail stores and preparing the company''s periodic and current reports with the SEC and complying with the Sarbanes Oxley Act. From May 2005 to October 2009, Mr. Brown served as the Corporate Controller of Franklin Covey Products where he developed and maintained the company''s internal controls over financial reporting structure in accordance with the control standards required under Section 404 of the Sarbanes Oxley Act. From July 2001 to May 2005, Mr. Brown served as an Assurance Senior at KPMG, LLP where he provided audit services to various clients in multiple industries. Mr. Brown holds a Bachelor of Arts in Accounting and Masters of Professional Accountancy from the University of Utah. Mr. Brown is a licensed CPA in Utah.
Brian Brown成为Co-diagnostics,Inc.首席财务官于2021年2月。从2020年7月到2021年2月,Brown先生担任A-Core Concrete Cutting,Inc.的首席财务官,在那里他的职责包括监督公司的会计和财务部门,并购,并负责财务预测和预算。从2019年8月到2019年12月,Brown先生担任Sportsman’;S Warehouse Holdings,Inc.的会计、财务和投资者关系副总裁,这是一家上市公司,在纳斯达克全球精选上市,代码为SPWH,他的职责包括监管公司的会计、财务和投资者关系部门,与美国证券交易委员会一起准备公司的年度、季度和当前报告,监督公司年度审计的所有方面,包括但不限于审计支持时间表的准备和审查,财务报表和脚注的准备,并为公司的独立审计师提供支持。从2009年10月到2019年8月,他担任Sportsman’;S Warehouse Holdings,Inc.的财务总监,在那里他协助公司于2014年4月进行首次公开募股,以及进行私人和第二次公开募股,根据《交易法》和《萨班斯·奥克斯利法案》,收购一批零售商店,并为公司准备提交给证券交易委员会的定期报告和最新报告。从2005年5月到2009年10月,他担任Franklin Covey Products的公司财务总监,在那里他根据Sarbanes Oxley Act第404条所要求的控制标准开发和维护公司的财务报告结构内部控制。从2001年7月到2005年5月,他担任毕马威会计师事务所(KPMG,LLP)的高级鉴证人员,在那里他为多个行业的各种客户提供审计服务。Brown先生拥有犹他大学的会计学文学学士学位和专业会计硕士学位。布朗先生是犹他州的注册会计师。
Brian Brown,became Co-Diagnostics, Inc. Chief Financial Officer in February 2021. From July 2020 until February 2021, Mr. Brown served as the Chief Financial Officer of A-Core Concrete Cutting, Inc. where his duties included overseeing the company''s accounting and finance departments, mergers and acquisitions and responsibility for financial forecasting and budgeting. From January 2020 to July 2020, Mr. Brown was an independent consultant. From August 2019 to December 2019, Mr. Brown served as the Vice President of Accounting, Treasury and Investor Relations at Sportsman''s Warehouse Holdings, Inc., a public company reporting on Nasdaq Global Select under the symbol SPWH, where his duties included overseeing the company''s accounting, treasury and investor relations departments, preparing the company''s annual, quarterly and current reports with the SEC, overseeing all aspects of the company''s annual audit, including, but not limited to, the preparation and review of audit support schedules, preparation of financial statements and footnotes, and providing support to the company''s independent auditors. From October 2009 to August 2019, Mr. Brown served as the Director of Finance of Sportsman''s Warehouse Holdings, Inc. where he assisted with the company''s initial public offering in April 2014 as well as effecting private and secondary public offerings, acquisitions of a group of retail stores and preparing the company''s periodic and current reports with the SEC and complying with the Sarbanes Oxley Act. From May 2005 to October 2009, Mr. Brown served as the Corporate Controller of Franklin Covey Products where he developed and maintained the company''s internal controls over financial reporting structure in accordance with the control standards required under Section 404 of the Sarbanes Oxley Act. From July 2001 to May 2005, Mr. Brown served as an Assurance Senior at KPMG, LLP where he provided audit services to various clients in multiple industries. Mr. Brown holds a Bachelor of Arts in Accounting and Masters of Professional Accountancy from the University of Utah. Mr. Brown is a licensed CPA in Utah.